Weight & body composition / emerging agents
Maridebart cafraglutide vs Retatrutide
Compare modality and evidence: long-acting antibody-peptide GLP-1 agonist/GIPR antagonist versus weekly tri-agonist peptide; cross-trial weight percentages.
At a glance
Maridebart cafraglutide
Retatrutide
Human evidence
Phase II data show substantial weight loss and HbA1c improvement in adults with obesity, including those with type 2 diabetes; GI tolerability improved with lower starting doses/escalation.
Randomized Phase II obesity data show major weight reduction. A 98-participant MASLD substudy also showed large dose-dependent liver-fat reductions, including >80% mean relative reduction at the two highest studied doses by week 24.
Research focus
Obesity, type 2 diabetes, cardiovascular outcomes
Obesity, weight management, metabolic disease
Regulatory status
Investigational; Phase 3 chronic-weight-management and cardiovascular studies are underway. No marketing authorisation identified.
Not FDA-approved as of this review; FDA states retatrutide has not been found safe and effective for any condition and cannot be used in US compounding.
Route / formulation
Maridebart cafraglutide is a long-acting antibody-peptide conjugate, not a conventional peptide vial.
Evidence applies to trial-grade retatrutide, not to unverified research-market vials or pens.
No direct head-to-head trial identified Compare modality and evidence: long-acting antibody-peptide GLP-1 agonist/GIPR antagonist versus weekly tri-agonist peptide; cross-trial weight percentages cannot establish superiority.